Compare ACADIA Pharmaceuticals Inc. (ACAD) vs abrdn Income Credit Strategies Fund (ACP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs abrdn Income Credit Strategies Fund — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.69 (market cap $5.07B), while abrdn Income Credit Strategies Fund trades at $5.15 (market cap $641.16M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 7.9× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays a 18.2% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | ACP | |
|---|---|---|
Market Cap | $5.07B | $641.16M |
Sector | Health | Financials |
52-Week High | $29.41 | $5.98 |
52-Week Low | $20.06 | $5.01 |
Enterprise Value | $4.19B | — |
Dividend Yield | — | 18.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.70, up 1.05% today, with a bullish technical trend and strong analyst support. The company reported robust Q2 2026 earnings, beating estimates with $0.18 EPS, and raised its 2026 revenue outlook. Revenue grew to $1.07 billion in 2025, with net income surging to $391 million, reflecting a 36.49% margin. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.
The outlook remains positive given earnings momentum and product sales growth, though high valuation multiples and recent negative cash flow pose risks. Analyst consensus targets $33.89, implying ~14% upside, with 70% recommending Buy. Key risks include clinical trial outcomes and competitive pressures in the biopharma sector.
ACP trades at $5.14, up 1.18% today, with a bearish technical signal from moving averages. The stock shows a low P/E of 7.74 and P/B of 0.9, indicating potential undervaluation, while a high net income margin of 95.31% and consistent dividend payments highlight financial strength. Recent news confirms dividend declarations for 2026.
The outlook is mixed; attractive valuation and dividends offer opportunity, but volatile revenue, an unsustainable distribution rate flagged by analysts, and high leverage pose significant risks. Investor sentiment is cautious due to these fundamental concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →
